Discovery of a Novel CCR5 Antagonist Lead Compound Through Fragment Assembly

CCR5, as the major co-receptor for HIV-1 entry, is an attractive novel target for the pharmaceutical industry in the HIV-1 therapeutic area. In this study, based on the structures of maraviroc and 1,4-bis(4-(7-chloroquinolin-4-yl)piperazin-1-yl)butane-1,4-dione (1), which was identified using struct...

Full description

Bibliographic Details
Main Authors: Hualiang Jiang, Jian Li, Xin Xie, Yu Zhang, Jin Zhu, Kunqian Yu, Enkun Zhou, Yanqing Liu
Format: Article
Language:English
Published: MDPI AG 2008-10-01
Series:Molecules
Subjects:
Online Access:http://www.mdpi.com/1420-3049/13/10/2426/
id doaj-9a4aeb148883486eb442bc86f10df21f
record_format Article
spelling doaj-9a4aeb148883486eb442bc86f10df21f2020-11-25T00:21:02ZengMDPI AGMolecules1420-30492008-10-01131024262441Discovery of a Novel CCR5 Antagonist Lead Compound Through Fragment AssemblyHualiang JiangJian LiXin XieYu ZhangJin ZhuKunqian YuEnkun ZhouYanqing LiuCCR5, as the major co-receptor for HIV-1 entry, is an attractive novel target for the pharmaceutical industry in the HIV-1 therapeutic area. In this study, based on the structures of maraviroc and 1,4-bis(4-(7-chloroquinolin-4-yl)piperazin-1-yl)butane-1,4-dione (1), which was identified using structure-based virtual screening in conjunction with a calcium mobilization assay, a series of novel small molecule CCR5 antagonists have been designed and synthesized through fragment assembly. Preliminary SARs were obtained, which are in good agreement with the molecular binding model and should prove helpful for future antagonist design. The novel scaffold presented here might also be useful in the development of maraviroc-derived second generation CCR5 antagonists.http://www.mdpi.com/1420-3049/13/10/2426/CCR5 antagonistfragment assemblyHIV-1molecular modeling
collection DOAJ
language English
format Article
sources DOAJ
author Hualiang Jiang
Jian Li
Xin Xie
Yu Zhang
Jin Zhu
Kunqian Yu
Enkun Zhou
Yanqing Liu
spellingShingle Hualiang Jiang
Jian Li
Xin Xie
Yu Zhang
Jin Zhu
Kunqian Yu
Enkun Zhou
Yanqing Liu
Discovery of a Novel CCR5 Antagonist Lead Compound Through Fragment Assembly
Molecules
CCR5 antagonist
fragment assembly
HIV-1
molecular modeling
author_facet Hualiang Jiang
Jian Li
Xin Xie
Yu Zhang
Jin Zhu
Kunqian Yu
Enkun Zhou
Yanqing Liu
author_sort Hualiang Jiang
title Discovery of a Novel CCR5 Antagonist Lead Compound Through Fragment Assembly
title_short Discovery of a Novel CCR5 Antagonist Lead Compound Through Fragment Assembly
title_full Discovery of a Novel CCR5 Antagonist Lead Compound Through Fragment Assembly
title_fullStr Discovery of a Novel CCR5 Antagonist Lead Compound Through Fragment Assembly
title_full_unstemmed Discovery of a Novel CCR5 Antagonist Lead Compound Through Fragment Assembly
title_sort discovery of a novel ccr5 antagonist lead compound through fragment assembly
publisher MDPI AG
series Molecules
issn 1420-3049
publishDate 2008-10-01
description CCR5, as the major co-receptor for HIV-1 entry, is an attractive novel target for the pharmaceutical industry in the HIV-1 therapeutic area. In this study, based on the structures of maraviroc and 1,4-bis(4-(7-chloroquinolin-4-yl)piperazin-1-yl)butane-1,4-dione (1), which was identified using structure-based virtual screening in conjunction with a calcium mobilization assay, a series of novel small molecule CCR5 antagonists have been designed and synthesized through fragment assembly. Preliminary SARs were obtained, which are in good agreement with the molecular binding model and should prove helpful for future antagonist design. The novel scaffold presented here might also be useful in the development of maraviroc-derived second generation CCR5 antagonists.
topic CCR5 antagonist
fragment assembly
HIV-1
molecular modeling
url http://www.mdpi.com/1420-3049/13/10/2426/
work_keys_str_mv AT hualiangjiang discoveryofanovelccr5antagonistleadcompoundthroughfragmentassembly
AT jianli discoveryofanovelccr5antagonistleadcompoundthroughfragmentassembly
AT xinxie discoveryofanovelccr5antagonistleadcompoundthroughfragmentassembly
AT yuzhang discoveryofanovelccr5antagonistleadcompoundthroughfragmentassembly
AT jinzhu discoveryofanovelccr5antagonistleadcompoundthroughfragmentassembly
AT kunqianyu discoveryofanovelccr5antagonistleadcompoundthroughfragmentassembly
AT enkunzhou discoveryofanovelccr5antagonistleadcompoundthroughfragmentassembly
AT yanqingliu discoveryofanovelccr5antagonistleadcompoundthroughfragmentassembly
_version_ 1725364260766220288